Jeevan Scientific Technology Ltd
BBSE:JSTL81.35
INR
-1.65
(-1.99%)
Jeevan Scientific Technology Ltd
BSE:JSTL
(Bombay Stock Exchange)
Recent
price
81.35
P/E
ratio
41.84
div
yld
- -
ROIC.AI
Capital Structure
INR
•
in mil. unless spec.Working Capital
INR
•
in mil. unless spec.Growth Rates
INR
•
in mil. unless spec.Quarterly Revenue
INR
•
in mil. unless spec.Quarterly Earnings Per Share
INR
•
in mil. unless spec.Quarterly Dividends Per Share
INR
•
in mil. unless spec.- Similar Companies
- Business
- Jeevan Scientific Technology Limited (JSTL), an independent clinical contract research organization headquartered in Hyderabad, India, and listed on the Bombay Stock Exchange (ticker: JSTL.BO), provides end-to-end clinical research solutions to pharmaceutical, biotechnology, medical device, cosmetics, and nutraceuticals companies worldwide; its core services encompass bioavailability and bioequivalence (BA/BE) studies including healthy and patient-based trials, food effect, age/gender effect, PK/PD endpoint, single/multiple ascending dose, and 505(b)(2) studies with bioanalytical method development via LC-MS/MS, statistical analysis using SAS/WinNonlin/CDISC, and sample management; clinical trial services from Phase II to IV covering patient PK trials, pharmacodynamic endpoint studies, post-marketing surveillance, investigator-initiated/real-world evidence studies, and support for complex generics/biosimilars; pharmacovigilance encompassing ICSR management, aggregate safety reporting (PADER/PSUR/PBRER), risk management plans, signal detection, medical information call centers, literature screening, data migration, and regulatory inspection support; clinical data management, biostatistics/statistical programming, medical writing, regulatory affairs, project management, and quality assurance; all delivered through a 132-bed clinical pharmacology unit (20,000 sq ft with NABL-accredited pathology lab, glucose clamp facilities, and biomedical freezers), a bioanalytical lab (10 LC-MS/MS systems), and operations compliant with USFDA (8 inspections), WHO (2), UK MHRA (1), CDSCO (5), NABL (3), and Oman regulatory approvals, having executed approximately 660 studies across diverse therapeutic areas. Founded in 1999 as Jeevan Softech Limited (name changed in March 2011) and entering clinical research in 2014, JSTL operates primarily from India with global client reach and employs around 244-288 staff. Recent developments include the 2023 establishment of subsidiary Nayas Laboratories Pvt. Ltd., a formulation R&D unit specializing in advanced drug delivery platforms, novel biomedical polymers, complex generics, 505(b)(2)/Para IV developments, and quality/regulatory services from conceptualization to commercialization; 2024 receipt of Oman regulatory approval for clinical/bioanalytical facilities; Q1 FY26 (ended June 2025) financial results showing standalone/consolidated losses with auditor review, managing director re-appointment, new independent director appointment, director resignation, 3 lakh ESOP grants, and AGM scheduled for September 27, 2025; board approvals in May 2024 for up to Rs. 15 crore investments/loans/guarantees/securities to related party SM Therapeutics Pvt. Ltd. (promoters Krishna Kishore Kuchipudi and K. Vanaja) for land development/construction to lease back for operations; and re-appointments of executive directors Jeevan Krishna Kuchipudi (CFO, effective February 2025 for 3 years) and Nageswar Rao Yarllagadda (effective June 2024 for 3 years).